RNA Synthesis IN-1 是一种多肽抗生素,可嵌入DNA双螺旋的小沟中,与DNA形成复合体,阻碍RNA多聚酶的功能,从而抑制RNA的合成。RNA Synthesis IN-1 抑制 DNA 修复,IC50 值为 0.42 μM。RNA Synthesis IN-1 也是一种自噬 (autophagy) 激活剂。
Plant Physiol. 2026 Aug 04; .
ACYR-mediated N4-acetylcytidine modification regulates cadmium responses in Arabidopsis.
Adv Sci (Weinh). 2026 Aug 27;e77393.
Sci Rep. 2026 Apr 27; .
Front Immunol. 2026 May 27;16/1601259.
FASEB J. 2026 May 31;40/e71945.
Phytomedicine. 2026 Jun 20; .
Qiteng Xiaozhuo granules activate mitophagy to alleviate chronic glomerulonephritis
Naunyn Schmiedebergs Arch Pharmacol. 2026 Jul 04; .
Plant Cell Rep. 2026 Jul 27; .
ABI5-activated ALKBH10B demethylates RAP2.6 mRNA to modulate Arabidopsis salt tolerance.
CNS Neurosci Ther. 2026 Jul;32/e71019.
Journal of Radiation Research and Applied Sciences. 2026 Apr 17;29:115310.
Cell Adh Migr. 2026 Dec;20:2650272.
Chin Med. 2026 Mar 18;21:00:00.000.
Cytokine. 2026 Apr 21;203:157157.
Int Immunopharmacol. 2026 Jun 15;179:116621.
Int J Biol Macromol. 2026 Feb 09;348:150816.
YTHDF2 promotes arsenic carcinogenesis through m6A-dependent SMAD7 decay and PRR5 escape from decay
Gene. 2026 Jan 24;986:150029.
Sci Rep. 2026 Jan;15:None.
Food Bioscience. 2026 Jan;75.
Arterioscler Thromb Vasc Biol. 2026 Jan;46:e323986.
Int J Biol Sci. 2026;22:1162-1185.
BioRxiv. 2023 Jan 28;526069.
BioRxiv. 2023 Sep 04;556177.
Brain Res. 2025 Feb 01;1872:150088.
Sci Rep. 2025 Dec 18; .
Biochim Biophys Acta Mol Basis Dis. 2025 Dec 01;1872:168129.
Analytical Chemistry. 2025 Dec 03;Vol 97:Issue 49.
Oncogene. 2025 Dec 08; .
Mol Ther. 2025 Dec 09; .
Methylated circPTK2 as a driver of fibroblast activation in pulmonary fibrosis.
Sci Adv. 2025 Dec 19;11:eadz6824.
J Ethnopharmacol. 2025 Nov 27;357:120948.
Cell Death Dis. 2025 Nov 23;16:852.
Immunol Res. 2025 Oct 15;73(1):145.
METTL14 aggravates pyroptosis in diabetic cardiomyopathy by promoting m6A modification of NLRP3
Autophagy. 2025 Oct 14; .
Kaohsiung J Med Sci. 2025 Sep 27; .
Clin Transl Med. 2025 Sep 26;15(10):e70483.
J Transl Med. 2025 Oct 02;23(1):1043.
J Immunother Cancer. 2025 Sep 22;13(9):e011893.
LTO1 and YAE1 regulate MHC-I expression via nonsense-mediated RNA decay in tumor cells
Sci Adv. 2025 Sep 12;11(37):eadw9519.
RNA binding protein DDX3X drives pancreatic cancer progression via the TLE2-MYL9 axis
J Inflamm Res. 2025 Aug 24;18:11577-11592.
Int J Biochem Cell Biol. 2025 Jun 15; .
METTL5-mediated m6A modification of SLC7A11 promotes cervical cancer by inhibiting ferroptosis
Exp Cell Res. 2025 Jun 10; .
LncRNA USP2-AS1 Facilitates Colorectal Cancer Development Through The PHLDA2/PI3K/AKT Axis
New Phytol. 2025 Jun 27; .
N4‐acetylcytidine mRNA modification regulates photosynthesis in plants
BMC Cancer. 2025 May 30;25(1):970.
Oncogene. 2025 May 26; .
Patent. CN118064581A 2024 May 24.
Hum Cell. 2025 Feb 26;38(2):62.
Biochem Pharmacol. 2025 Jun;236:116867.
Cell Death Discov. 2025 Mar 13;11(1):101.
Clin Transl Med. 2025 Feb 26;15(3):e70249.
Biochem Biophys Res Commun. 2025 Apr 09;763:151770.
J Med Virol. 2025 Apr 29;97(5):e70356.
Cell Rep. 2025 Apr 23;44(5):115611.
Cell Signal. 2025 Mar;127:111533.
Pharmacol Res. 2024 Dec 01;210:107509.
METTL14-mediated m6A modification enhances USP22-ERα axis to drive breast cancer malignancy
Mol Med. 2025 Jan 24;31(1):24.
J Gastroenterol Hepatol. 2024 Oct 15.
Int J Biol Macromol. 2024 Oct 30.
Cancer Cell Int. 2024 Sep 19;24(1):321.
The role of KRT7 in metastasis and prognosis of pancreatic cancer
Oncogene. 2024 Oct 10.
Hum Mol Genet. 2024 Aug 31.
Free Radic Biol Med. 2024 Aug 23;224:130-143.
Adv Sci (Weinh). 2024 Sep 04;e2401118.
CRISPR/dCas13(Rx) Derived RNA N6-methyladenosine (m6A) Dynamic Modification in Plant
Mol Carcinog. 2024 Aug 02.
Plant Growth Regulation. 2024 Aug 04.
Dissecting the roles of increased mRNA m6A methylation in autotetraploidization in Stevia rebaudiana
Plant Physiol. 2024 Aug 07.
N6-methyladenosine RNA modification regulates photoperiod sensitivity in cotton
Cell Mol Life Sci. 2024 Jun 16.
Cancer Letters. 2024 Jun 22;16(1):2334967.
J Exp Clin Cancer Res. 2024 Jun 20;471:134331.
Cell Mol Life Sci. 2024 Jun 9;81(1):253.
Cancer Lett. 2024 Jun 3;596:217004.
Exp Mol Med. 2024 Jun 3.
J Biol Chem. 2024 Mar 25;300(5):107226.
Epstein-Barr virus suppresses N6-Methyladenosine modification of TLR9 to promote immune evasion
Cell Death Dis. 2024 Mar 20;15(3):229.
Exp Mol Med. 2024 Mar 1.
Cell Death Dis. 2024 Mar 11;15(3):205.
GINS2 regulates temozolomide chemosensitivity via the EGR1/ECT2 axis in gliomas
Adv Sci (Weinh). 2024 Jan;e2207435.
Scientific Reports. 2024 Jan ;9;14(1):904.
J Nutr Biochem. 2024 Jan;3:125:109563.
Cell Death Dis. 2024 Jan;13;15(1):43.
Cell Biol Toxicol. 2023 Oct;39(5):2165-2181.
Virus Res. 2024 Jan 2;339:199273.
Mol Biomed. 2023 Nov 17;4(1):42.
Oncogene. 2023 Nov 7.
Cell Death Dis. 2023 Sep 21;14(9):619.
Sci Total Environ. 2023 Sep 18;167202.
BMC Complementary Medicine and Therapies. 2023 Jul 1.
Clin Epigenetics. 2023 Jul 5;15(1):109.
FTO-dependent m6A regulates muscle fiber remodeling in an NFATC1–YTHDF2 dependent manner
J Transl Med. 2023 Jun 23;21(1):407.
Plant Cell. 2023 Jun 27;koad189.
N4-acetylation of cytidine in (m) RNA plays essential roles in plants
J Orthop Sci. 2023 May 27;S0949-2658(23)00133-1.
Front Immunol. 2023 Mar 30;14:1144774.
J Hazard Mater. 2023 May 6;455:131543.
Clin Epigenetics. 2023 Jul 5;15(1):109.
FTO-dependent m6A regulates muscle fiber remodeling in an NFATC1-YTHDF2 dependent manner
J Exp Clin Cancer Res. 2023 May 19;42(1):127.
J Cell Biochem. 2023 Feb;124(2):239-253.
Biomed Pharmacother. 2023 May;161:114575.
Plant Biotechnol J. 2023 Mar 22.
Molecules. 2022 May 16;27(10):3182.
A Novel Strategy for Regulating mRNA's Degradation via Interfering the AUF1's Binding to mRNA
iScience. 2022 Nov 10;25(12):105552.
Cells. 2022 Sep 27;11(19):3008.
Antiviral Res. 2023 Jan;209:105482.
Int J Biol Sci. 2023 Jan 1;19(2):691-704.
Adv Sci (Weinh). 2023 Jan;10(2):e2201724.
Cell Biol Toxicol. 2022 Feb 28;1-17.
Mol Cancer. 2022 Feb 14;21(1):49.
Cancer Lett. 2021 Dec 28;523:135-147.
Theranostics. 2020 Apr 27;10(13):5671-5686.
| 分子量 | 1255.42 |
| 中文名称 | RNA合成抑制剂1 |
| 溶解性(仅列举部分溶剂) | DMSO 90 mg/mL |
| 储存条件 | -20°C, protect from light |
| 运输方式 | 冰袋运输,根据产品的不同,可能会有相应调整。 |
*不同实验中用到的溶剂可能不同,具体实验所需溶剂及溶解方法请参考相关文献描述。
RNA Synthesis IN-1 (a substitute for Actinomycin D) 是一种多肽抗生素,可嵌入DNA双螺旋的小沟中,与DNA形成复合体,阻碍RNA多聚酶的功能,从而抑制RNA的合成、转录、转运,使细胞周期停滞在G1期。RNA Synthesis IN-1 是自噬的激活剂,可在淋巴细胞性白血病中诱导p53依赖性细胞的死亡。
RNA Synthesis IN-1 具有抗菌和抗肿瘤作用。RNA Synthesis IN-1 是一种 RNA 和蛋白质合成抑制剂,能够抑制细菌的蛋白合成,可以直接结合转录起始复合体中单链或双链 DNA 的鸟嘌呤基团,抑制 DNA 依赖的 RNA 聚合酶活力,干扰 DNA 的转录过程,从而抑制 mRNA 合成。RNA Synthesis IN-1 抑制 DNA 修复,IC50 值为 0.42 μM。RNA Synthesis IN-1 也是一种自噬 (autophagy) 激活剂。
RNA Synthesis IN-1 (0.06 mg/kg; 腹腔注射,连续 14 天) 导致慢性淋巴细胞白血病小鼠模型肿瘤消退。
下述溶液配置方法仅为基于分子量计算出的理论值。不同产品在配置溶液前,需考虑其在不同溶剂中的溶解度限制。
| 浓度/溶剂体积/质量 | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 0.7965 mL | 3.9827 mL | 7.9655 mL |
| 5 mM | 0.1593 mL | 0.7965 mL | 1.5931 mL |
| 10 mM | 0.0797 mL | 0.3983 mL | 0.7965 mL |
*吸湿的DMSO对产品的溶解度有显著影响,请使用新开封的DMSO;
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
建议您制定动物给药及实验方案时,尽量参考已发表的相关实验文献(溶剂种类及配比众多,简单地溶解目的化合物,并不能解决动物给药依从性、体内生物利用度、组织分布等相关问题,未必能保证目的化合物在动物体内充分发挥生物学效用)。
体内实验的工作液,建议您现用现配,当天使用;如在配制过程中出现沉淀、析出现象,可以通过超声和(或)加热的方式助溶。
切勿一次性将产品全部溶解。
请在下面的计算器中,输入您的动物实验相关数据并点击计算,即可得到该实验的总需药量和工作液终浓度。
例如您给药剂量是10 mg/kg,平均每只动物的体重为20 g,每只动物的给药体积是100 μL,动物数量为20只,则该动物实验的总需药量为4 mg,工作液终浓度为2 mg/mL。
1:鉴于实验过程的损耗,建议您至少多配1-2只动物的量;
2:为该产品最终给药时的浓度。
以上参考文献由AI整理,仅供参考,AbMole 尚未独立确认这些文献的准确性。